Eli Lilly’s latest Alzheimer’s drug may be next to receive FDA approval. But investors should know about some of the hurdles ahead.

Was this article helpful?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Search Window